MoonLake Securities Suit Advances in SDNY as Firms Urge Investors to Seek Lead Role by Dec. 15

Overview

• Peters v. MoonLake Immunotherapeutics, No. 1:25-cv-08612, is pending in the Southern District of New York asserting claims under Sections 10(b) and 20(a).
• Investor notices set a December 15, 2025 deadline to move for lead-plaintiff status, with outreach from Bleichmar Fonti & Auld, Rosen, Robbins Geller, Glancy Prongay & Murray, and the Law Offices of Howard G. Smith.
• Plaintiffs allege MoonLake misrepresented sonelokimab’s differentiation despite shared IL‑17A/IL‑17F targets with UCB’s BIMZELX and touted tissue penetration that did not translate to superior efficacy.
• MoonLake reported on September 28, 2025 that Phase 3 VELA week‑16 results were disappointing, including VELA‑2 missing its primary endpoint, and the stock closed at $6.24 on September 29 after a nearly 90% decline.
• No class has been certified, and investors are not represented by court‑appointed counsel unless and until a lead plaintiff is appointed.